Mitsubishi Tanabe Pharma America Inc. announced findings from a new analysis evaluating the impact of symptom progression on the ability of people with amyotrophic lateral sclerosis to independently conduct activities of daily living. The findings were shared during a virtual presentation at the 2021 Muscular Dystrophy Association Clinical & Scientific Conference. For the analysis, 21 neurologists examined de-identified medical record data for 166 ALS patients in the U.S. to retroactively assess demographics, symptoms, caregiver status, hospitalizations, ability to perform ADLs, emotional well-being, and number of patient-reported falls. Of the patients whose records were reviewed, 54% (90 patients) were dependent on a caregiver to assist with at least one ADL. Participating neurologists were surveyed and submitted blinded patient data into a study database. Compared with other symptom groups, and based on descriptive analyses, a significant association was observed between the number of respiratory symptoms and likelihood of ADL dependence. In addition, ADL-dependent patients experienced a greater number of hospitalizations (28.1% vs. 4.7%; p<0.001) and falls (1.2% vs. 0.5%; p<0.001) in the prior 12 months, compared with ADL-independent patients. A larger proportion of ADL-dependent patients also had poorer emotional well-being (87% vs. 66%; p=<0.001) and had expressed suicidal thoughts (19% vs. 8%; p=0.045) compared with ADL-independent patients. The survey database is not based on a truly random sample of physicians and patients. Moreover, patients included in the survey may not represent the general ALS population.